Table 4

Relationship between lipids and markers of disease activity in RA patients treated with RTX (n=49) during 6 months RTX

Atherogenic index b (SE)Total cholesterol b (SE)HDL cholesterol b (SE)
Disease activity marker
DAS280.11 (0.06)**−0.11 (0.05)*−0.05 (0.01)*
C reactive protein−0.01 (0.06)−0.01 (0.00)*−0.003 (0.001)*
Prednisone dosage (mg)−0.01 (0.11)0.01 (0.12)0.002 (0.003)
Apo B to Apo A-I β (SE)Apo B β (SE)Apo A-I β (SE)
Disease activity marker
DAS280.02 (0.01)*−0.004 (0.009)−0.05 (0.01)*
C reactive protein0.001 (0.001)−0.001 (0.001)−0.005 (0.001)*
Prednisone dosage (mg)−0.001 (0.001)−0.001 (0.002)0.000 (0.003)
  • Values represent change (β) per unit disease activity marker over time.

  • * p<0.05,

  • ** p<0.10.

  • DAS28, 28 joint disease activity score; HDL, high density lipoprotein; RA, rheumatoid arthritis; RTX, rituximab.